Spark Investment Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Spark Investment Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-913	Closed	-$186K	–	305
2020 Q1	$186K	Buy	+913	New	+$291K	0.1%	237
2019 Q3	–	Sell	-496	Closed	-$157K	–	530
2019 Q2	$157K	Buy	496 +158	+47%	+$54.7K	0.01%	482
2019 Q1	$141K	Hold	338	–	–	0.01%	541
2018 Q4	$103K	Buy	+338	New	+$109K	0.01%	558

Other funds holding EIGR

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Spark Investment Management's EIGR Position: Q2 2020 in Review

Spark Investment Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2020, closing a stake of 913 shares — an estimated $186K sold.

Spark Investment Management first reported a position in EIGR in Q4 2018 and held it in 4 quarters. The position peaked at $186K in Q1 2020. 94 funds tracked by Wall St. Rank hold EIGR as of Q2 2020.

Spark Investment Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Spark Investment Management sold 913 Eiger BioPharmaceuticals, Inc. shares in Q2 2020, an estimated $186K.
Spark Investment Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 4 quarters.
Spark Investment Management's Eiger BioPharmaceuticals, Inc. position peaked at $186K in Q1 2020.
94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.